Oncogenex Amends IPO Terms

Oncogenex Technologies Inc., a Vancouver-based drug company focused on cancer therapeutics, has amended its proposed IPO terms to five million common shares being offered at between $7.50 and $7.50 per share. It previously had been planning to offer 4.5 million shares being at between $10 and $12 per share. Oncogenex plans to trade on both the Nasdaq and TSX, with RBC Capital Markets serving as lead underwriter. Shareholders include Ventures West, BDC Venture Capital, GrowthWorks, HIG Capital and Milestone Medica Corp. www.oncogenex.ca